Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
RESEARCH TOOLSreports
Holding FDMT?
Track your performance easily
FDMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.68 - $36.25
Previous CloseN/A
Volume165.32K
Average Volume (3M)937.53K
Market Cap
$225.59M
Enterprise Value$123.49M
Total Cash (Recent Filing)$23.85M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Mar 31, 2025EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.73
Shares Outstanding46,227,710
10 Day Avg. Volume758,247
30 Day Avg. Volume937,528
Standard Deviation0.33
R-Squared0.15
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13705.16
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue6.86K
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda-0.87
Forecast
1Y Price Target
$30.00Price Target Upside495.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
4D Molecular Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe determination to pursue a single Phase 3 trial in diabetic macular edema with FDA feedback, combined with pivotal support from the wet age-related macular degeneration program, is viewed as a streamlined path to potential labeling.
Financial PositionResource reallocation has extended the cash runway into 2028, supporting full execution of key programs in wet age-related macular degeneration and early-stage development in diabetic macular edema and cystic fibrosis.
Regulatory And Market OpportunityRegulatory alignment with US and EU regulators on the registrational program for 4D-150 in wet age-related macular degeneration is a key de-risking event, potentially allowing for a broad label and highlighting a large commercial opportunity.
Bears Say
Competitive LandscapeThe wAMD/DME competitive landscape is increasingly crowded, pressuring FDMT's thesis.
Market ChallengesReal-world setting could pose non-clinical obstacles, potentially hampering the commercial opportunity for wAMD gene therapies.
Safety And Durability ConcernsUpcoming 4D-150 readouts are more likely to drive downside than upside due to lower injection-free rate and safety risks with longer follow-up.
---
Ownership Overview
14.99% Insiders
13.25% Mutual Funds
1.41% Other Institutional Investors
58.27% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $4.67 and its highest was $36.25 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $225.59M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Mar 31, 2025 which is in 72 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.676 by -$0.114.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 46,227,710 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.676. Following the earnings report the stock price went up 4.021%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Among the largest hedge funds holding 4D Molecular Therapeutics’s share is RA Capital Management. It holds 4D Molecular Therapeutics’s shares valued at 55M.
---
4D Molecular Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (495.24% Upside)
$30.00 (495.24% Upside)
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.62%
12-Months-Change
Fundamentals
Return on Equity
-25.95%
Trailing 12-Months
Asset Growth
67.04%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.
---
FDMT Stock 12 Month Forecast
Average Price Target
$30.00
▲(495.24% Upside)
Technical Analysis
Adverum Biotechnologies
―
Krystal Biotech
―
Rocket Pharmaceuticals
―
Crispr Therapeutics AG
―
uniQure
―
Abeona Therapeutics
―
Best Analysts Covering FDMT
1 Year
1 Year Success Rate
5/17 ratings generated profit
1 Year Average Return
-21.41%
reiterated a buy rating 5 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -21.41% per trade.
---